Currently, there are 82.40M common shares owned by the public and among those 74.42M shares have been available to trade.
The company’s stock has a 5-day price change of -45.99% and -65.53% over the past three months. STRO shares are trading -55.97% year to date (YTD), with the 12-month market performance down to -81.71% lower. It has a 12-month low price of $1.25 and touched a high of $6.13 over the same period. STRO has an average intraday trading volume of 979.71K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -46.80%, -53.81%, and -73.66% respectively.
Institutional ownership of Sutro Biopharma Inc (NASDAQ: STRO) shares accounts for 68.90% of the company’s 82.40M shares outstanding.
It has a market capitalization of $67.87M and a beta (3y monthly) value of 1.50. The earnings-per-share (ttm) stands at -$1.62. Price movements for the stock have been influenced by the stock’s volatility, which stands at 12.83% over the week and 9.54% over the month.
Earnings per share for the fiscal year are expected to increase by 18.99%, and 43.33% over the next financial year. EPS should grow at an annualized rate of 24.97% over the next five years, compared to 21.96% over the past 5-year period.
Looking at the support for the STRO, a number of firms have released research notes about the stock. Wedbush stated their Neutral rating for the stock in a research note on March 14, 2025, with the firm’s price target at $8-$2. BofA Securities was of a view on March 14, 2025 that the stock is Underperform, while BofA Securities gave the stock Buy rating on May 08, 2024, issuing a price target of $12. Deutsche Bank on their part issued Buy rating on November 09, 2023.
